NTLA (Intellia Therapeutics) Float Percentage Of Total Shares Outstanding: 79.32% (As of Jul. 03, 2026)


NTLA Intellia Therapeutics Inc NTLA
71 GF Score
Price $17.56
GF Value $20.57
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Intellia Therapeutics Float Percentage Of Total Shares Outstanding?

Intellia Therapeutics NTLA +1.89% 71 Float Percentage Of Total Shares Outstanding is 79.32% as of Jul. 03, 2026. GuruFocus rates NTLA with a GF Score™ of 71/100 and a GF Value™ of $20.57 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Intellia Therapeutics's float shares is 110.83 Mil. Intellia Therapeutics's total shares outstanding is 139.72 Mil. Intellia Therapeutics's float percentage of total shares outstanding is 79.32%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Intellia Therapeutics's Insider Ownership is 2.85%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Intellia Therapeutics's Institutional Ownership is 88.41%.

NTLA
71GF Score
Intellia Therapeutics Inc NTLA
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Intellia Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=110.83/139.72
=79.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 79.32% mean?
Intellia Therapeutics (NTLA) has a Float Percentage Of Total Shares Outstanding of 79.32% as of Jul. 03, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Intellia Therapeutics' current Float Percentage Of Total Shares Outstanding is 79.32%. Overall, Intellia Therapeutics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Float Percentage Of Total Shares Outstanding compare to MLYS and VCEL?
Intellia Therapeutics' Float Percentage Of Total Shares Outstanding of 79.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Float Percentage Of Total Shares Outstanding is 79.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.57, compared to a current price of $17.56 — trading 14.6% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 79.32%. Intellia Therapeutics' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Float Percentage Of Total Shares Outstanding is 79.32% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $17.56 is trading 14.6% below its estimated GF Value™ of $20.57. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

  • Float Percentage Of Total Shares Outstanding: 79.32%
  • GF Value™: $20.57 vs. price of $17.56 (14.6% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Other Exchanges 0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
71GF Score

Get the complete analysis for NTLA

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.56
Price
$20.57
GF Value